Press Releases
TEL AVIV, Israel, Nov. 5, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it will host a Key Opinion Leader breakfast meeting on Friday, November 7, 2014, from 8:00 a.m. to 9:30 a.m. Eastern Standard Time at the NY Palace Hotel in New York City.
The meeting will feature a keynote address by Professor Rohit Loomba, MD, MHSc., who will discuss the advantages of early treatment of non-alcoholic steatohepatitis (NASH) to prevent the advancement into fibrosis and cirrhosis, and the associated cardio-metabolic complications. Professor Loomba is a member of Galmed's Scientific Advisory Board and an expert in the clinical management of chronic liver diseases. He holds a joint appointment in the Division of Gastroenterology in the Department of Medicine and the Division of Epidemiology in the Department of Family and Preventive Medicine at the University of California at San Diego School of Medicine. Professor Loomba is also the founding director of the UCSD non-alcoholic fatty liver disease, or NAFLD, Translational Research Unit and the founder and principal investigator of the San Diego Integrated NAFLD Research Consortium. His research focuses on all aspects of non-alcoholic fatty liver disease including aging, epidemiology, genetic and environmental predisposition, natural history, and treatment of NASH, and has been funded by various industry agencies, associations and foundations, including the National Institutes of Health, American Gastroenterology Association and National Science Foundation. In addition, since 2009, Professor Loomba has been the Principal Investigator for adult hepatology for the NIDDK-sponsored NASH Clinical Research Network and is currently a member of the American Association for the Study of Liver Diseases.
Key members of Galmed's executive management team, including Chief Executive Officer, Allen Baharaff, and Chief Medical Officer, Dr. Maya Halperin, MD, MA, will also be in attendance and intend to provide an overview of Galmed and its current operations.
The event is intended for institutional investors and sell-side analysts only. To reserve a place, please contact Veronica Molina at 212-915-2567 or via e-mail at vmolina@lifesciadvisors.com.
A live webcast of the event will be available at http://lifesci.rampard.com/20141107 and will also be accessible through the Investors section of Galmed's website at http://galmedpharma.investorroom.com/events-and-presentations.
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the U.S. Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared effective by the SEC on March 12, 2014, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update any forward-looking statements.
SOURCE Galmed Pharmaceuticals Ltd.